## Purpose: The purpose of this randomized, crossover study was to compare the bioavailability of a generic and an innovator formulation of nizatidine 300 mg capsules under fasting conditions. ## Methods: Twenty blood samples per period were collected from 20 healthy, arab male volunteers over 16
A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers
β Scribed by Jason T. McConville; Lee-Ann Hodges; Tamara Jones; Janet P. Band; Bridget O'Mahony; Blythe Lindsay; Alistair C. Ross; Alastair J. Florence; Adrian J. Stanley; Michael J. Humphrey; Clive G. Wilson; Howard N.E. Stevens
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 272 KB
- Volume
- 98
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
β¦ Synopsis
Three time-delayed capsule (TDC) formulations were investigated in a pharmacoscintigraphic study, using a three-way crossover design in eight healthy male volunteers. Additionally, the pulsed release of a TDC was investigated with time-lapse photography, using a nondisintegrating riboflavin tablet. The photographic study indicated how the release characteristics of the TDC relied on the erosion of a tablet containing hypromellose (HPMC). Each TDC was duel radio labelled with indium-111 and technetium-99 m DTPA complexes, to observe drug release scintigraphically (theophylline was a marker compound). Three formulations, having in vitro dissolution release times of 1.8, 2.9 or 4.0 h were shown to compare favourably with mean in vivo scintigraphic release times of 2.7, 3.0 and 4.0 h for each formulation containing 20, 24 or 35% (w/w) HPMC concentrations respectively. An increase in HPMC concentration was associated with a delayed technetium release time, and followed the same rank order as the in vitro dissolution study. Observed radiolabel dispersion always occurred in the small intestine. In conclusion, the study established that the TDC performs and demonstrates an in vitro-in vivo correlation. Additionally, time and site of release were accurately visualized by gamma scintigraphy, and confirmed with determination of theophylline absorption.
π SIMILAR VOLUMES
## Background: This phase i study was designed to determine the bioavailability and bioequivalence of 400 mg eudorlin extra\* (ibuprofen) in comparison to two reference formulations (400 mg nurofen forte and 400 mg migrΓ€nin after single dose administration under fasting conditions in healthy subjec
## Background Interferon (IFN) alpha conjugation to polyethylene glycol (PEG) results in a better pharmacokinetic profile and efficacy. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of a new, locally developed, 40-kDa PEG-IFN alpha-2b preparation wi
The pharmacokinetics of ibuprofen enantiomers were investigated in a crossover study in which seven healthy male volunteers received single oral doses of 800 mg racemic ibuprofen as a soluble granular formulation (sachet) containing L-arginine (designated trade name: Spedifen), 400 mg (-)R-ibuprofen
In 12 healthy volunteers the pharmacokinetic parameters of two new sustained-release formulations of disodiummonofluorophosphate (MFP) (B and C) were compared with those of a nonsustained-release reference preparation (A). This randomized study had a single-dose, triple-cross over design and consist